Crossmark

Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use

Crossref DOI link: https://doi.org/10.1038/s41380-026-03602-7

Published Online: 2026-04-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ramaekers, Johannes G. https://orcid.org/0000-0003-4553-376X
Kuypers, Kim P. C. https://orcid.org/0000-0001-7634-3809
Vollenweider, Franz X. https://orcid.org/0000-0001-9053-6164
License Information

Text and Data Mining valid from 2026-04-08

Version of Record valid from 2026-04-08
More Information

Article History

Received: 17 October 2025

Revised: 11 March 2026

Accepted: 30 March 2026

First Online: 8 April 2026

Competing interest

: The authors declare no competing interests.

Document is current

Any future updates will be listed below